On March 22, 2011 the U.S. Supreme Court handed down a decision which is likely to have serious repercussions for companies in the bio/pharma tech space. In MATRIXX INITIATIVES, INC., ET AL. v. SIRACUSANO ET AL., the Court rejected Matrixx argument that reports regarding the adverse effect of Zicam, its leading revenue generating product, were not statistically significant and therefore not material.
Noting that the analysis of materiality under the securities laws in fact specific, the Court appears to have relied heavily on two factors:
1. The methodologies and requirements ...
Blog Editors
Recent Updates
- Podcast: Can FTC’s Non-Compete Ban Survive Without Chevron Deference? – Employment Law This Week
- Video: Chevron Deference Overturned - Employment Law This Week
- California District Court Rules That Software Vendor Is Subject to Title VII, the ADA, the ADEA
- Pumping the Brakes: New York Seeks to Curb AI Acceleration in Labor Market
- Video: California Governor’s PAGA Deal: What Employers Need to Know - Employment Law This Week